Causes Horlick's cancer

GlaxoSmithKline Consumer Healthcare aims to reach 85 percent of smokers worldwide with smoking cessation offers

Mumbai, India, Jan. 28 / PRNewswire / - - Experts gather at the World Conference on Tobacco OR Health to discuss reducing global tobacco consumption and access to treatment options

GlaxoSmithKline (GSK) Consumer Healthcare today announced plans to increase the availability of its therapeutic nicotine products to reach over 800 million people worldwide over the next four years. That announcement came at the World Conference on Tobacco OR Health (WCTOH) being held this year in India, a country that is projected to see nearly one million tobacco deaths a year from 2010 (1). Opinion leaders from around the world gather at this triennial conference to discuss global initiatives to reduce tobacco consumption and the extraordinary health impact it poses.

"GSK intends to reach 85 percent of smokers around the world with our smoking cessation offerings by 2013. We are committed to working with local experts to find ways to maximize access to our life-saving products and their effects," explained Dr. Dr. med. Raj Mishra, Vice President Research and Development at GlaxoSmithKline Consumer Healthcare. "We hope that by bringing our therapeutic nicotine products to market worldwide, we will do our part to reduce the global burden of tobacco-related diseases by helping more people quit smoking."

A World Health Organization (WHO) World Tobacco Report concluded that tobacco consumption was the fastest growing in low-income countries, as the population is growing rapidly and the tobacco industry is particularly active there. According to the report, one billion smokers are predicted to die prematurely from tobacco consumption this century if decisive action is not taken to help smokers quit smoking (2). As part of the official WHO strategy, the organization calls on opinion leaders in the fight against tobacco use to support smoking cessation through three different treatment options: telephone counseling services, cessation programs for primary health services and pharmaceutical therapies, including, for example, the use of therapeutic nicotine products (2).

"Many people around the world want to quit smoking, but they do not have the information or resources to effectively address it. The increased availability of products that help people quit is a positive step towards being smoke-free World, "says Dr. Randeep Guleria, Professor in the Medical School of the All India Institute of Medical Sciences. "With the recently passed smoking ban in enclosed public spaces, the Indian government is sending a clear signal to the country's 120 million adult smokers (1) that it wants to curb the continued widespread use of tobacco in India. Support for the use of Withdrawal products like therapeutic nicotine is the next step in freeing our country from this dangerous health problem. "

The global effects of persistent tobacco use are staggering:

  • Tobacco use is the number one preventable cause of death and disease, which is predicted to cause 1 billion deaths in the 21st century unless effective measures are taken (2).
  • More than a third of all adults worldwide (i.e. more than 1.1 billion people) smoke; 80 percent of them in low and middle income countries (2).
  • If current smoking behavior does not change, this will result in around 10 million deaths annually by 2020, 70 percent of them in developing countries (2).
  • In the United States alone, tobacco addiction has an annual cost of nearly $ 200 billion - over $ 96 billion in direct health costs and $ 97 billion in lost productivity (3).

Safety and effectiveness of GlaxoSmithKline's therapeutic nicotine

Therapeutic nicotine, including NiQuitin lozenges and patches (sold under the Nicabate brand in Australia), can relieve withdrawal symptoms during smoking cessation (3). Research results from over 110 clinical studies with more than 40,000 participants have confirmed the safety and efficacy profile of therapeutic nicotine products, provided they are used according to the instructions (4). United States, United Kingdom, and World Health Organization (WHO) guidelines list nicotine therapeutic products as the first-line treatment for nicotine addiction (2,3,5). To date, more than six million people around the world have used therapeutic nicotine products from GSK as a supplement to help them quit smoking, significantly reducing their risk of developing cancer or other tobacco-related diseases (6).

These products are specifically designed to break the addiction cycle by gradually releasing nicotine into the body in a controlled manner, thereby helping alleviate withdrawal symptoms.

Information about GlaxoSmithKline Consumer Healthcare

GlaxoSmithKline Consumer Healthcare is one of the world's largest over-the-counter healthcare products companies. Its more than 30 well-known brands include the leading tobacco cessation products NicoDerm (R) CQ and Commit (R), NiQuitin and Nicabate as well as many products that are in every medicine cabinet, such as Aquafresh (R), Panadol (R), Crocin (R), Horlicks (R) and Sensodyne (R). GlaxoSmithKline Consumer Healthcare continues to develop innovative products to help all smokers find the supportive therapy that is right for them. Because this is how you can achieve your goal of living smoke-free in the future.

Information on GlaxoSmithKline

GlaxoSmithKline is a leading global research-driven pharmaceutical and healthcare company. The company's aim is to improve people's quality of life by enabling them to live more active, longer and healthier lives.

(1) Jha, et al; A Nationally Representative Case - Control Study of Smoking and Death in India; NEJM, 2008

(2) World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008. Geneva: World Health Organization; 2008 [cited March 21, 2008]. Available at: http://www.who.int/tobacco/mpower/en/

(3) Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD:
U.S. Department of Health and Human Services. Public Health Service. May 2008.

(4) Silagy et al. Nicotine replacement therapy for smoking cessation (Cochrane Review). In: The Cochrane Library, Volume 1, 2004. Chichester, UK: John Wiley & Sons, LTD.

(5) NICE. 2002. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. Technology Appraisal Guidance - No.39.

(6) Centers for Disease Control and Prevention. Use of FDA-approved pharmacologic treatments for tobacco dependence. Morbidity and Mortality Weekly Report 2000; 49: 665-668.

Contact person: Mark Polisky
GolinHarris
+1-312-729-4417
[email protected]
Jennifer May
GlaxoSmithKline
Consumer Healthcare
+1-412-200-3729
[email protected]

Inquiries & contact:

Mark Polisky of GolinHarris, +1-312-729-4417,
[email protected], for GlaxoSmithKline; or Jennifer May from
GlaxoSmithKline Consumer Healthcare, + 1-412-200-3729,
[email protected]